


PATIENT NAME: ANJANA KAURA	RA REF. DOCTOR : SELF		
	ACCESSION NO : 0002WD0116	27 AGE/SEX : 45 Years Female	
	PATIENT ID : ANJAF0209772	DRAWN :07/04/2023 08:48:35	
	CLIENT PATIENT ID:	RECEIVED :07/04/2023 08:50:01	
	ABHA NO :	REPORTED :10/04/2023 17:54:18	
Test Report Status <u>Final</u>	Results Bio	blogical Reference Interval Units	
MEDI WHEEL FULL BODY HEALTH CHECKUP	ABOVE 40FEMALE		
XRAY-CHEST			
IMPRESSION	NO ABNORMALITY DETECTED		
TMT OR ECHO			
TMT OR ECHO	GOOD LV SYSTOLIC FUNCTION	AT REST. NO RWMA	
	LVEF 60 % ALL VALVES STRUCTURALLY NO		
	NO EVIDENCE OF PE/CLOT/VEG		
ECG			
ECG	WITHIN NORMAL LIMITS		
MAMOGRAPHY (BOTH BREASTS)			
MAMOGRAPHY BOTH BREASTS	DENSE BREASTS DUE TO PRED PARENCHYMA	OMINANT FIBROGLANDULAR	
MEDICAL HISTORY			
RELEVANT PRESENT HISTORY	ITCHING ON SKIN ON AND OFF		
RELEVANT PAST HISTORY	TYPHOID IN 2004		
RELEVANT PERSONAL HISTORY	NOT SIGNIFICANT		
MENSTRUAL HISTORY (FOR FEMALES)	REGULAR		
LMP (FOR FEMALES)	09/03/2023		
RELEVANT FAMILY HISTORY	HYPETENSION		
HISTORY OF MEDICATIONS	NOT SIGNIFICANT		
ANTHROPOMETRIC DATA & BMI			
HEIGHT IN METERS	1.55	mts	
WEIGHT IN KGS.	48.8	Kgs	
BMI	Be 18 25	1I & Weight Status as followg/sqmts low 18.5: Underweight .5 - 24.9: Normal .0 - 29.9: Overweight .0 and Above: Obese	
GENERAL EXAMINATION			
MENTAL / EMOTIONAL STATE	NORMAL		
PHYSICAL ATTITUDE	NORMAL		
GENERAL APPEARANCE / NUTRITIONAL STATUS	HEALTHY		
BUILT / SKELETAL FRAMEWORK	AVERAGE		

therkl

Dr. J N Shukla ,MBBS, AFIH Consultant Physician



Page 1 Of 24










PATIENT NAME: ANJANA KAURA	REF. DOCTOR : SELF		
	ACCESSION NO : 0002WD011627	AGE/SEX :45 Years Female	
	PATIENT ID : ANJAF0209772	DRAWN :07/04/2023 08:48:3	
	CLIENT PATIENT ID:	RECEIVED :07/04/2023 08:50:0	
	ABHA NO :	REPORTED :10/04/2023 17:54:18	
Test Report Status <u>Final</u>	Results Biologic	al Reference Interval Units	
FACIAL APPEARANCE	NORMAL		
SKIN	RASH		
UPPER LIMB	NORMAL		
LOWER LIMB	NORMAL		
NECK	NORMAL		
NECK LYMPHATICS / SALIVARY GLANDS	NOT ENLARGED OR TENDER		
THYROID GLAND	NOT ENLARGED		
CAROTID PULSATION	NORMAL		
TEMPERATURE	NORMAL		
PULSE	80/MIN REGULAR, ALL PERIPHERAL I BRUIT	PULSES WELL FELT, NO CAROTID	
RESPIRATORY RATE	NORMAL		
CARDIOVASCULAR SYSTEM			
BP	130/90 MM HG (SUPINE)	mm/Hg	
PERICARDIUM	NORMAL		
APEX BEAT	NORMAL		
HEART SOUNDS	S1, S2 HEARD NORMALLY		
MURMURS	ABSENT		
RESPIRATORY SYSTEM			
SIZE AND SHAPE OF CHEST	NORMAL		
MOVEMENTS OF CHEST	SYMMETRICAL		
BREATH SOUNDS INTENSITY	NORMAL		
BREATH SOUNDS QUALITY	VESICULAR (NORMAL)		
ADDED SOUNDS	ABSENT		
PER ABDOMEN			
APPEARANCE	NORMAL		
VENOUS PROMINENCE	ABSENT		
LIVER	NOT PALPABLE		
SPLEEN	NOT PALPABLE		
HERNIA	ABSENT		
CENTRAL NERVOUS SYSTEM			
HIGHER FUNCTIONS	NORMAL		

Herkl

Dr. J N Shukla ,MBBS, AFIH Consultant Physician



Page 2 Of 24









PATIENT NAME: ANJANA KAURA	REF. D	OCTOR : S	ELF		
	ACCESSION NO : 0002WD01	1627	AGE/SEX	:45 Years	Female
	PATIENT ID : ANJAF02097	72	DRAWN	:07/04/2023	08:48:35
	CLIENT PATIENT ID:			:07/04/2023	
	ABHA NO :		REPORTED	:10/04/2023	17:54:18
Test Report Status <u>Final</u>	Results	Biological	Reference	e Interval	Units
CRANIAL NERVES	NORMAL				
CEREBELLAR FUNCTIONS	NORMAL				
SENSORY SYSTEM	NORMAL				
MOTOR SYSTEM	NORMAL				
REFLEXES	NORMAL				
MUSCULOSKELETAL SYSTEM					
SPINE	NORMAL				
JOINTS	NORMAL				
BASIC EYE EXAMINATION					
CONJUNCTIVA	NORMAL				
EYELIDS	NORMAL				
EYE MOVEMENTS	NORMAL				
CORNEA	NORMAL				
DISTANT VISION RIGHT EYE WITHOUT GLASSES	REDUCE VISUAL ACUITY (6/	24)			
DISTANT VISION LEFT EYE WITHOUT GLASSES	WITHIN NORMAL LIMIT (6/6	)			
NEAR VISION RIGHT EYE WITHOUT GLASSES	WITHIN NORMAL LIMIT (N6)				
NEAR VISION LEFT EYE WITHOUT GLASSES	REDUCE VISUAL ACUITY (N1	LO)			
COLOUR VISION	NORMAL (17/17)				
BASIC ENT EXAMINATION					
EXTERNAL EAR CANAL	NORMAL				
TYMPANIC MEMBRANE	NORMAL				
NOSE	NO ABNORMALITY DETECTED	)			
SINUSES	NORMAL				
THROAT	NO ABNORMALITY DETECTED	)			
TONSILS	NOT ENLARGED				
BASIC DENTAL EXAMINATION					
TEETH	NORMAL				
GUMS	HEALTHY				
SUMMARY					
RELEVANT HISTORY	NOT SIGNIFICANT				
RELEVANT GP EXAMINATION FINDINGS	NOT SIGNIFICANT				

Herkl

Dr. J N Shukla ,MBBS, AFIH Consultant Physician



Page 3 Of 24

View Report

View Details

۵5



錏



PATIENT NAME: ANJANA KAURA	REF. DOCTOR :	SELF
	ACCESSION NO : 0002WD011627	AGE/SEX : 45 Years Female
	PATIENT ID : ANJAF0209772	DRAWN :07/04/2023 08:48:35
	CLIENT PATIENT ID:	RECEIVED : 07/04/2023 08:50:01
	ABHA NO :	REPORTED :10/04/2023 17:54:18
Test Report Status <u>Final</u>	Results Biological	Reference Interval Units
RELEVANT LAB INVESTIGATIONS	LOW HAEMOGLOBIN (11.6) RAISED EOSINOPHILS (8) RAISED ESR (22) RAISED HDL CHOLESTEROL (63) LOW SODIUM (135)	
RELEVANT NON PATHOLOGY DIAGNOSTICS	USG-ECTOPIC AND MALROTATED LEFT I	KIDNEY

REMARKS / RECOMMENDATIONS

LOW HAEMOGLOBIN,RAISED ESR,MILD ANEMIA,LOW SODIUM MONITOR BLOOD PRESSURE FOLLOW UP WITH PHYSICIAN/DERMATOLOGIST



Dr. J N Shukla ,MBBS, AFIH Consultant Physician



Page 4 Of 24

View Report

View Details



PERFORMED AT : SRL Ltd PRIME SQUARE BUILDING,PLOT NO 1,GAIWADI INDUSTRIAL ESTATE,S.V. ROAD,GOREGAON (W) Mumbai, 400062 MAHARASHTRA, INDIA Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956



PATIENT NAME : AN	NJANA KAURA	REF. DOCTOR	: SELF
		ACCESSION NO : 0002WD011627	AGE/SEX : 45 Years Female
		PATIENT ID : ANJAF0209772	DRAWN :07/04/2023 08:48:35
		CLIENT PATIENT ID:	RECEIVED : 07/04/2023 08:50:01
		ABHA NO :	REPORTED :10/04/2023 17:54:18
Test Report Status	<u>Final</u>	Results	Units
MEDI WHEEL FULL E	BODY HEALTH	CHECKUP ABOVE 40FEMALE	
ULTRASOUND ABDO	MEN		
ULTRASOUND ABDO	MEN		
ECTOPIC AND MAL	ROTATEDIE	T KIDNEY AS DESCRIBED.	

HIS JURI-THIS REPORT CARRIES THE SIGNATURE OF OUR LABORATORY DIRECTOR. THIS IS AN INVIOLABLE FEATURE OF OUR LAB MANAGEMENT SOFTWARE. HOWEVER, ALL EXAMINATIONS AND INVESTIGATIONS HAVE BEEN CONDUCTED BY OUR PANEL OF DOCTORS. \*\*\*

terkl

Dr. J N Shukla , MBBS, AFIH **Consultant Physician** 



Page 5 Of 24

View Details



**PERFORMED AT :** SRL Ltd PRIME SQUARE BUILDING, PLOT NO 1, GAIWADI INDUSTRIAL ESTATE, S.V. ROAD, GOREGAON (W) Mumbai, 400062 MAHARÁSHTRA, INDIA Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956





**PATIENT NAME: ANJANA KAURA REF. DOCTOR : SELF** ACCESSION NO : 0002WD011627 AGE/SEX :45 Years Female :07/04/2023 08:48:35 PATIENT ID : ANJAF0209772 DRAWN CLIENT PATIENT ID: RECEIVED :07/04/2023 08:50:01 REPORTED :10/04/2023 17:54:18 ABHA NO : **Test Report Status** <u>Final</u> Results **Biological Reference Interval** Units

HAEMATOLOGY - CBC					
MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE					
BLOOD COUNTS, EDTA WHOLE BLOOD					
HEMOGLOBIN (HB) METHOD : PHOTOMETRIC MEASUREMENT	11.6 Low	12.0 - 15.0	g/dL		
RED BLOOD CELL (RBC) COUNT METHOD : COULTER PRINCIPLE	4.46	3.8 - 4.8	mil/µL		
WHITE BLOOD CELL (WBC) COUNT METHOD : COULTER PRINCIPLE	6.10	4.0 - 10.0	thou/µL		
PLATELET COUNT METHOD : ELECTRONIC IMPEDENCE & MICROSCOPY	274	150 - 410	thou/µL		
RBC AND PLATELET INDICES					
HEMATOCRIT (PCV) METHOD : CALCULATED PARAMETER	35.6 Low	36.0 - 46.0	%		
MEAN CORPUSCULAR VOLUME (MCV) METHOD : DERIVED PARAMETER FROM RBC HISTOGRAM	79.8 Low	83.0 - 101.0	fL		
MEAN CORPUSCULAR HEMOGLOBIN (MCH) METHOD : CALCULATED PARAMETER	26.0 Low	27.0 - 32.0	pg		
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC) METHOD : CALCULATED PARAMETER	32.6	31.5 - 34.5	g/dL		
RED CELL DISTRIBUTION WIDTH (RDW) METHOD : DERIVED PARAMETER FROM RBC HISTOGRAM	13.9	11.6 - 14.0	%		
MENTZER INDEX	17.9				
MEAN PLATELET VOLUME (MPV) METHOD : DERIVED PARAMETER FROM PLATELET HISTOGRAM	8.0	6.8 - 10.9	fL		
WBC DIFFERENTIAL COUNT					
NEUTROPHILS METHOD : VCSN TECHNOLOGY/ MICROSCOPY	50	40 - 80	%		
LYMPHOCYTES METHOD : VCSN TECHNOLOGY/ MICROSCOPY	35	20 - 40	%		
MONOCYTES METHOD : VCSN TECHNOLOGY/ MICROSCOPY	6	2.0 - 10.0	%		
EOSINOPHILS METHOD : VCSN TECHNOLOGY/ MICROSCOPY	8 High	1.0 - 6.0	%		



Dr. Reena Mittal, MD Senior Consultant Hematopathologist



Dr. Sushant Chikane Consultant Pathologist



View Report

View Details



PERFORMED AT : SRL Ltd PRIME SQUARE BUILDING,PLOT NO 1,GAIWADI INDUSTRIAL ESTATE,S.V. ROAD,GOREGAON (W) Mumbai, 400062 MAHARASHTRA, INDIA Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956





PATIENT NAME: ANJANA KAURA **REF. DOCTOR : SELF** ACCESSION NO : 0002WD011627 AGE/SEX :45 Years Female PATIENT ID DRAWN :07/04/2023 08:48:35 : ANJAF0209772 CLIENT PATIENT ID: RECEIVED :07/04/2023 08:50:01 ABHA NO REPORTED :10/04/2023 17:54:18 : Test Report Status Results **Biological Reference Interval** Units <u>Final</u>

PACODUTIC	-	0 1	%
BASOPHILS	1	0 - 1	%
METHOD : VCSN TECHNOLOGY/ MICROSCOPY			
ABSOLUTE NEUTROPHIL COUNT	3.10	2.0 - 7.0	thou/µL
METHOD : CALCULATED PARAMETER			
ABSOLUTE LYMPHOCYTE COUNT	2.20	1.0 - 3.0	thou/µL
METHOD : CALCULATED PARAMETER			
ABSOLUTE MONOCYTE COUNT	0.37	0.2 - 1.0	thou/µL
METHOD : CALCULATED PARAMETER			
ABSOLUTE EOSINOPHIL COUNT	0.49	0.02 - 0.50	thou/µL
METHOD : CALCULATED PARAMETER	0115	0.02	
ABSOLUTE BASOPHIL COUNT	0.06	0.02 - 0.10	thou/µL
	0.00	0.02 - 0.10	thou, pe
METHOD : CALCULATED PARAMETER			
NEUTROPHIL LYMPHOCYTE RATIO (NLR)	1.4		
METHOD : CALCULATED			

Interpretation(s) BLOOD COUNTS,EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology.

RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13) from Beta thalassaemia trait

(<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait.

WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease.

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients ; A.-P. Yang, et al.; International Immunopharmacology 84 (2020) 106504 This ratio element is a calculated parameter and out of NABL scope.

Dr. Reena Mittal, MD Senior Consultant Hematopathologist

**Dr. Sushant Chikane Consultant Pathologist** 





Vie<u>w Report</u>

Page 7 Of 24



**PERFORMED AT :** SRL Ltd PRIME SQUARE BUILDING, PLOT NO 1, GAIWADI INDUSTRIAL ESTATE, S.V. ROAD, GOREGAON (W) Mumbai, 400062 MAHARÁSHTRA, INDIA Tel : 9111591115, Fax CIN - U74899PB1995PLC045956



0 - 20



mm at 1 hr

**REF. DOCTOR : SELF PATIENT NAME: ANJANA KAURA** ACCESSION NO : 0002WD011627 AGE/SEX :45 Years Female :07/04/2023 08:48:35 PATIENT ID : ANJAF0209772 DRAWN CLIENT PATIENT ID: RECEIVED :07/04/2023 08:50:01 ABHA NO REPORTED :10/04/2023 17:54:18 : Test Report Status Results **Biological Reference Interval** Units <u>Final</u>

HAEMATOLOGY

22 High

# MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE

# **ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE**

BLOOD

E.S.R

METHOD : AUTOMATED (PHOTOMETRICAL CAPILLARY STOPPED FLOW KINETIC ANALYSIS)

Interpretation(s)

ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD-TEST DESCRIPTION :

Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic; it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change.

# TEST INTERPRETATION

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging

Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias, Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis). In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum. Decreased in: Polycythermia vera, Sickle cell anemia

### LIMITATIONS

False elevated ESR : Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia False Decreased : Poikilocytosis, (SickleCells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs(Quinine, salicylates)

**REFERENCE** :

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition; 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin; 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis, 10th edition.

Dr. Reena Mittal, MD Senior Consultant Hematopathologist

**Dr. Sushant Chikane Consultant Pathologist** 





View Repor

Page 8 Of 24



**PERFORMED AT :** SRL Ltd PRIME SQUARE BUILDING, PLOT NO 1, GAIWADI INDUSTRIAL ESTATE, S.V. ROAD, GOREGAON (W) Mumbai, 400062 MAHARÁSHTRA, INDIA Tel : 9111591115, Fax CIN - U74899PB1995PLC045956





**PATIENT NAME: ANJANA KAURA REF. DOCTOR : SELF** ACCESSION NO : 0002WD011627 AGE/SEX :45 Years Female PATIENT ID DRAWN :07/04/2023 08:48:35 : ANJAF0209772 CLIENT PATIENT ID: RECEIVED :07/04/2023 08:50:01 ABHA NO REPORTED :10/04/2023 17:54:18 : **Test Report Status** Results **Biological Reference Interval** Units <u>Final</u>

	IMMUNOHAEMATOLOGY
MEDI WHEEL FULL BODY HEALTH CHECKU	ABOVE 40FEMALE
ABO GROUP & RH TYPE, EDTA WHOLE BLO	OD
ABO GROUP METHOD : HAEMAGGLUTINATION (AUTOMATED)	В
RH TYPE METHOD : HAEMAGGLUTINATION (AUTOMATED)	POSITIVE

Interpretation(s) ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same.

The test is performed by both forward as well as reverse grouping methods.

**Dr. Sushant Chikane Consultant Pathologist** 



Page 9 Of 24

V<u>iew Report</u>



**PERFORMED AT :** SRL Ltd PRIME SQUARE BUILDING, PLOT NO 1, GAIWADI INDUSTRIAL ESTATE, S.V. ROAD, GOREGAON (W) Mumbai, 400062 MAHARÁSHTRA, INDIA Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956






**PATIENT NAME: ANJANA KAURA REF. DOCTOR : SELF** ACCESSION NO : 0002WD011627 AGE/SEX :45 Years Female :07/04/2023 08:48:35 PATIENT ID : ANJAF0209772 DRAWN CLIENT PATIENT ID: RECEIVED :07/04/2023 08:50:01 REPORTED :10/04/2023 17:54:18 ABHA NO : **Test Report Status Final** Results **Biological Reference Interval** Units

	BIOCHEMISTRY		
MEDI WHEEL FULL BODY HEALTH CHECKUP	ABOVE 40FEMALE		
GLYCOSYLATED HEMOGLOBIN(HBA1C), EDT BLOOD	A WHOLE		
HBA1C METHOD : ION- EXCHANGE HPLC	5.4	Non-diabetic Adult < Pre-diabetes 5.7 - 6.4 Diabetes diagnosis: > Therapeutic goals: < Action suggested : > (ADA Guideline 2021	4 • or = 6.5 7.0 • 8.0
ESTIMATED AVERAGE GLUCOSE(EAG) GLUCOSE FASTING,FLUORIDE PLASMA	108.3	< 116	mg/dL
FBS (FASTING BLOOD SUGAR)	91	Normal <100 Impaired fasting gluc 125 Diabetes mellitus: > more than 1 occassio (ADA guidelines 2021	= 126 (on n)

METHOD : SPECTROPHOTOMETRY HEXOKINASE

S.S. Wadal

Dr. Sneha Wadalkar,M.D (Reg.no.MMC2012/06/1868) Junior Biochemist



Page 10 Of 24













PATIENT NAME: ANJANA KAURA **REF. DOCTOR : SELF** ACCESSION NO : 0002WD011627 AGE/SEX :45 Years Female : ANJAF0209772 PATIENT ID DRAWN :07/04/2023 08:48:35 CLIENT PATIENT ID: RECEIVED :07/04/2023 08:50:01 ABHA NO REPORTED :10/04/2023 17:54:18 : **Test Report Status Final** Results **Biological Reference Interval** Units



METHOD : SPECTROPHOTOMETRY HEXOKINASE

S.S. Wadal

Dr. Sneha Wadalkar, M.D (Reg.no.MMC2012/06/1868) Junior Biochemist



Page 11 Of 24









**PATIENT NAME: ANJANA KAURA REF. DOCTOR : SELF** ACCESSION NO : 0002WD011627 AGE/SEX :45 Years Female :07/04/2023 08:48:35 PATIENT ID : ANJAF0209772 DRAWN CLIENT PATIENT ID: RECEIVED :07/04/2023 08:50:01 REPORTED :10/04/2023 17:54:18 ABHA NO : Biological Reference Interval **Test Report Status Final** Results Units

	GLUCOSE, POST-PRANDIAL, PLASMA		
160			
96 - 64 - 22 E 32 -	81 •	98	
0	05-JUL-2015 13:30	07-APR-2023 14:22	
NormalRange	Date>		
LIPID PROFILE, SERUM			
CHOLESTEROL, TOTAL	150	Desirable : < 200 Borderline : 200 - 239 High : > / = 240	mg/dL
METHOD : SPECTROPHOTOMETRY, ENZY	MATIC COLORIMETRIC - CHOLETSEROL OXIDASE, ES	ERASE, PEROXIDASE	
TRIGLYCERIDES	51	Normal: < 150 Borderline high: 150 - 19 High: 200 - 499 Very High: >/= 500	mg/dL 99
METHOD : SPECTROPHOTOMETRY, ENZY	MATIC ENDPOINT WITH GLYCEROL BLANK		
HDL CHOLESTEROL	63 High	At Risk: < 40 Desirable: > or = 60	mg/dL
	OGENEOUS DIRECT ENZYMATIC COLORIMETRIC		
CHOLESTEROL LDL	77	Optimal : < 100 Near optimal/above optir 100-129 Borderline high : 130-15 High : 160-189 Very high : = 190	
METHOD : CALCULATED PARAMETER		-, 5	

METHOD : CALCULATED PARAMETER

S.S. Wadal

Dr. Sneha Wadalkar, M.D (Reg.no.MMC2012/06/1868) Junior Biochemist











PATIENT NAME: ANJANA KAURA **REF. DOCTOR : SELF** ACCESSION NO : 0002WD011627 AGE/SEX :45 Years Female PATIENT ID DRAWN :07/04/2023 08:48:35 : ANJAF0209772 CLIENT PATIENT ID: RECEIVED :07/04/2023 08:50:01 ABHA NO REPORTED :10/04/2023 17:54:18 : **Test Report Status** Results **Biological Reference Interval** Units <u>Final</u> NON HDL CHOLESTEROL 87 mg/dL Desirable : < 130Above Desirable : 130 -159 Borderline High : 160 - 189

		High : 190 - 219 Very high : > / = 220	
METHOD : CALCULATED PARAMETER			
VERY LOW DENSITY LIPOPROTEIN METHOD : CALCULATED PARAMETER	10.0	< or = 30.0 mg/dL	
CHOL/HDL RATIO	2.4 Low	Low Risk : 3.3 - 4.4 Average Risk : 4.5 - 7.0 Moderate Risk : 7.1 - 11.0 High Risk : > 11.0	
METHOD : CALCULATED PARAMETER			
LDL/HDL RATIO	1.4	Desirable/Low Risk : 0.5 - 3.0 Borderline/Moderate Risk : 3.1 - 6.0 High Risk : > 6.0	

METHOD : CALCULATED PARAMETER

## Interpretation(s)

Serum lipid profile is measured for cardiovascular risk prediction. Lipid Association of India recommends LDL-C as primary target and Non HDL-C as co-primary treatment target. Risk Stratification for ASCVD (Atherosclerotic cardiovascular disease) by Lipid Association of India

Risk Category			
Extreme risk group	A.CAD with $> 1$ feature of high risk group		
	B. CAD with > 1 feature of Very high risk	group or recurre	nt ACS (within 1 year) despite LDL-C < or =
	50 mg/dl or polyvascular disease		
Very High Risk	1. Established ASCVD 2. Diabetes with 2	2 major risk facto	rs or evidence of end organ damage 3.
	Familial Homozygous Hypercholesteroler	nia	
High Risk	1. Three major ASCVD risk factors. 2. I	Diabetes with 1 m	ajor risk factor or no evidence of end organ
	damage. 3. CKD stage 3B or 4. 4. LDL >	>190 mg/dl 5. Ex	treme of a single risk factor. 6. Coronary
	Artery Calcium - CAC >300 AU. 7. Lipoprotein a >/= 50mg/dl 8. Non stenotic carotid plaque		
Moderate Risk	2 major ASCVD risk factors		
Low Risk	0-1 major ASCVD risk factors		
Major ASCVD (Ath	erosclerotic cardiovascular disease) Risk	Factors	
1. Age $>$ or $=$ 45 year	rs in males and $>$ or $= 55$ years in females	3. Current Ci	garette smoking or tobacco use
2. Family history of p	premature ASCVD	4. High blood	pressure
5. Low HDL			
lewer treatment goals	s and statin initiation thresholds based on	the risk categori	es proposed by LAI in 2020.
Risk Group	Treatment Goals		Consider Drug Therapy

8. wadal

Dr. Sneha Wadalkar,M.D (Reg.no.MMC2012/06/1868) Junior Biochemist







Vie<u>w Report</u>








PATIENT NAME : AN	JANA KAURA	REF.	DOCTOR : S	SELF		
		ACCESSION NO : 0002WD01	1627	AGE/SEX	:45 Years	Female
		PATIENT ID : ANJAF0209	772	DRAWN	:07/04/2023	08:48:35
		CLIENT PATIENT ID:		RECEIVED	:07/04/2023	08:50:01
		ABHA NO :		REPORTED	:10/04/2023	17:54:18
Test Report Status	<u>Final</u>	Results	Biological	Reference	Interval L	Jnits

	LDL-C (mg/dl)	Non-HDL (mg/dl)	LDL-C (mg/dl)	Non-HDL (mg/dl)
Extreme Risk Group Category A	<50 (Optional goal	< 80 (Optional goal	>OR = 50	>OR = 80
	< OR = 30)	< OR = 60)		
Extreme Risk Group Category B	<or 30<="" =="" td=""><td><or 60<="" =="" td=""><td>&gt; 30</td><td>&gt;60</td></or></td></or>	<or 60<="" =="" td=""><td>&gt; 30</td><td>&gt;60</td></or>	> 30	>60
Very High Risk	<50	<80	>OR= 50	>OR= 80
High Risk	<70	<100	>OR= 70	>OR=100
Moderate Risk	<100	<130	>OR=100	>OR=130
Low Risk	<100	<130	>OR=130*	>OR=160
*After an adequate non-pharmacolog				
References: Management of Dyslipio	daemia for the Preventi	on of Stroke: Clinical Pr	ractice Recommenda	ations from the Lipid Association
India. Current Vascular Pharmacolog				
LIVER FUNCTION PROFILE, SE	RUM			
BILIRUBIN, TOTAL		0.49	Upto 1.2	mg/dL
METHOD : SPECTROPHOTOMETRY, COLORI	IMETRIC -DIAZO METHOD		·	
BILIRUBIN, DIRECT		0.25	< or = 0.	3 mg/dL
METHOD : SPECTROPHOTOMETRY, JENDRA	SSIK & GROFE - DIAZOTIZ			
				ma (di
BILIRUBIN, INDIRECT		0.24	0.0 - 0.9	mg/dL
METHOD : CALCULATED PARAMETER				
TOTAL PROTEIN		6.9	6.0 - 8.0	g/dL
METHOD : SPECTROPHOTOMETRY, COLORI	IMETRIC -BIURET, REAGENT	BLANK, SERUM BLANK		
ALBUMIN		4.2	3.97 - 4.9	94 g/dL
METHOD : SPECTROPHOTOMETRY, BROMO	CRESOL GREEN(BCG) - DYE	BINDING		
GLOBULIN		2.7	2.0 - 3.5	g/dL
METHOD : CALCULATED PARAMETER		217	210 515	
		1.6	1.0 - 2.1	RATIO
ALBUMIN/GLOBULIN RATIO		1.0	1.0 - 2.1	KATIO
METHOD : CALCULATED PARAMETER				
ASPARTATE AMINOTRANSFER	,	17	Upto 32	U/L
METHOD : SPECTROPHOTOMETRY, WITHOU	UT PYRIDOXAL PHOSPHATE	ACTIVATION( P5P) - IFCC		
ALANINE AMINOTRANSFERAS	E (ALT/SGPT)	13	Upto 33	U/L
METHOD : SPECTROPHOTOMETRY, WITHOU	UT PYRIDOXAL PHOSPHATE	ACTIVATION( P5P) - IFCC		
ALKALINE PHOSPHATASE		63	35 - 104	U/L
METHOD : SPECTROPHOTOMETRY, PNPP, A	MP BUFFER - IECC		00 10	-,
		13	< 40	U/L
GAMMA GLUTAMYL TRANSFER	. ,	-		0/L
METHOD : SPECTROPHOTOMETRY, ENZYMA	ATIC COLORIMETRIC - G-GL			
LACTATE DEHYDROGENASE		156	< 223	U/L
METHOD : SPECTROPHOTOMETRY, LACTAT	e to pyruvate - UV-IFCC			

# **BLOOD UREA NITROGEN (BUN), SERUM**

S.S. Wadal

Dr. Sneha Wadalkar, M.D (Reg.no.MMC2012/06/1868) Junior Biochemist



Page 14 Of 24



Details







PATIENT NAME: ANJANA KAURA **REF. DOCTOR : SELF** ACCESSION NO : 0002WD011627 AGE/SEX :45 Years Female PATIENT ID DRAWN :07/04/2023 08:48:35 : ANJAF0209772 CLIENT PATIENT ID: RECEIVED :07/04/2023 08:50:01 ABHA NO REPORTED :10/04/2023 17:54:18 : **Test Report Status** Results **Biological Reference Interval** Units <u>Final</u> 8 6 - 20 mg/dL **BLOOD UREA NITROGEN** METHOD : SPECTROPHOTOMETRY, UREASE -COLORIMETRIC **CREATININE, SERUM** mg/dL CREATININE 0.66 0.60 - 1.10 METHOD : SPECTROPHOTOMETRY, JAFFE'S ALKALINE PICRATE KINETIC - RATE BLANKED - IFCC-IDMS STANDARIZED **BUN/CREAT RATIO BUN/CREAT RATIO** 12.00 8 - 15 METHOD : CALCULATED PARAMETER URIC ACID, SERUM URIC ACID 3.9 2.4 - 5.7 mg/dL METHOD : SPECTROPHOTOMETRY, ENZYMATIC COLORIMETRIC- URICASE **TOTAL PROTEIN, SERUM** TOTAL PROTEIN g/dL 6.9 6.0 - 8.0METHOD : SPECTROPHOTOMETRY, COLORIMETRIC -BIURET, REAGENT BLANK, SERUM BLANK ALBUMIN, SERUM 3.97 - 4.94 g/dL ALBUMIN 4.2 METHOD : SPECTROPHOTOMETRY, BROMOCRESOL GREEN(BCG) - DYE BINDING GLOBULIN g/dL GLOBULIN 2.7 2.0 - 3.5 METHOD : CALCULATED PARAMETER ELECTROLYTES (NA/K/CL), SERUM SODIUM, SERUM 135 Low 136 - 145 mmol/L METHOD : ISE INDIRECT POTASSIUM, SERUM 4.10 3.5 - 5.1 mmol/L METHOD : ISE INDIRECT 102 mmol/L CHLORIDE, SERUM 98 - 106 METHOD : ISE INDIRECT Interpretation(s) Sodium Chloride Potassium

8.wadal

Dr. Sneha Wadalkar,M.D (Reg.no.MMC2012/06/1868) Junior Biochemist

Page 15 Of 24

w Repor









PATIENT NAME: ANJANA KAURA	REF. DOCT	FOR : SELF
	ACCESSION NO : 0002WD01162	AGE/SEX :45 Years Female
	PATIENT ID : ANJAF0209772	DRAWN :07/04/2023 08:48:35
	CLIENT PATIENT ID:	RECEIVED :07/04/2023 08:50:01
	ABHA NO :	REPORTED :10/04/2023 17:54:18
Test Report Status <u>Final</u>	Results Biol	ogical Reference Interval Units

Decreased in:CCF, cirrhosis, vomiting, diarrhea, excessive sweating, salt-losing nephropathy, adrenal insufficiency, nephrotic syndrome, water intoxication, SIADH. Drugs: thiazides, diuretics, ACE inhibitors, chlorpropamide, carbamazepine, anti depressants (SSRI), antipsychotics.	Decreased in: Low potassium intake,prolonged vomiting or diarrhea, RTA types I and II, hyperaldosteronism, Cushing's syndrome,osmotic diuresis (e.g., hyperglycemia),alkalosis, familial periodic paralysis,trauma (transient).Drugs: Adrenergic agents, diuretics.	Decreased in: Vomiting, diarrhea, renal failure combined with salt deprivation, over-treatment with diuretics, chronic respiratory acidosis, diabetic ketoacidosis, excessive sweating, SIADH, salt-losing nephropathy, porphyria, expansion of extracellular fluid volume, adrenalinsufficiency, hyperaldosteronism, metabolic alkalosis. Drugs: chronic laxative, corticosteroids, diuretics.
Increased in: Dehydration (excessivesweating, severe vomiting or diarrhea),diabetes mellitus, diabetesinsipidus, hyperaldosteronism, inadequate water intake. Drugs: steroids, licorice,oral contraceptives.	Increased in: Massive hemolysis, severe tissue damage, rhabdomyolysis, acidosis, dehydration,renal failure, Addison's disease, RTA type IV, hyperkalemic familial periodic paralysis. Drugs: potassium salts, potassium- sparing diuretics,NSAIDs, beta-blockers, ACE inhibitors, high- dose trimethoprim-sulfamethoxazole.	Increased in: Renal failure, nephrotic syndrome, RTA, dehydration, overtreatment with saline, hyperparathyroidism, diabetes insipidus, metabolic acidosis from diarrhea (Loss of HCO3-), respiratory alkalosis, hyperadrenocorticism. Drugs: acetazolamide, androgens, hydrochlorothiazide, salicylates.
Interferences: Severe lipemia or hyperproteinemi, if sodium analysis involves a dilution step can cause spurious results. The serum sodium falls about 1.6 mEq/L for each 100 mg/dL increase in blood glucose.	Interferences: Hemolysis of sample, delayed separation of serum, prolonged fist clenching during blood drawing, and prolonged tourniquet placement. Very high WBC/PLT counts may cause spurious. Plasma potassium levels are normal.	Interferences:Test is helpful in assessing normal and increased anion gap metabolic acidosis and in distinguishing hypercalcemia due to hyperparathyroidism (high serum chloride) from that due to malignancy (Normal serum chloride)

### Interpretation(s)

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-Used For:

Evaluating the long-term control of blood glucose concentrations in diabetic patients.

Diagnosing diabetes.
 Identifying patients at increased risk for diabetes (prediabetes).

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range.

1. eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.

2. eAG gives an evaluation of blood glucose levels for the last couple of months. 3. eAG is calculated as eAG (mg/dl) = 28.7 \* HbA1c - 46.7

### HbA1c Estimation can get affected due to :

1. Shortened Erythrocyte survival : Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss, hemolytic anemia) will falsely lower HbA1c test results. Fructosamine is recommended in these patients which indicates diabetes control over 15 days. 2. Vitamin C & E are reported to falsely lower test results (possibly by inhibiting glycation of hemoglobin.

3. Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods, falsely increasing results.

4. Interference of hemoglobinopathies in HbA1c estimation is seen in

a) Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.

b) Heterozygous state detected (D10 is corrected for HbS kHbC trait.) c) HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy GLUCOSE FASTING.FLUORIDE PLASMA-**TEST DESCRIPTION** 

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the urine.

8. wadal

Dr. Sneha Wadalkar, M.D (Reg.no.MMC2012/06/1868) Junior Biochemist



Page 16 Of 24



**PERFORMED AT :** SRL Ltd PRIME SQUARE BUILDING, PLOT NO 1, GAIWADI INDUSTRIAL ESTATE, S.V. ROAD, GOREGAON (W) Mumbai, 400062 MAHARÁSHTRA, INDIA Tel : 9111591115, Fax CIN - U74899PB1995PLC045956





MC-2010

PATIENT NAME : AN	JANA KAURA		<b>REF. DOCTOR</b>	: SELF		
		ACCESSION NO :	0002WD011627	AGE/SEX	:45 Years	Female
		PATIENT ID :	ANJAF0209772	DRAWN	:07/04/2023	08:48:35
		CLIENT PATIENT	ID:	RECEIVED	:07/04/2023	08:50:01
		ABHA NO :		REPORTED	:10/04/2023	17:54:18
						~
Test Report Status	<u>Final</u>	Results	Biologic	al Reference	e Interval U	nits

Increased in: Diabetes mellitus, Cushing's syndrome (10 - 15%), chronic pancreatitis (30%). Drugs: corticosteroids, phenytoin, estrogen, thiazides.

Decreased in :Pancreatic islet cell disease with increased insulin, insulinoma, adrenocortical insufficiency, hypopituitarism, diffuse liver disease, malignancy (adrenocortical, stomach, fibrosarcoma), infant of a diabetic mother, enzyme deficiency

diseases(e.g.galactosemia), Drugs-insulin, ethanol, propranolol; sulfonylureas, tolbutamide, and other oral hypoglycemic agents.

NOTE: While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals. Thus, glycosylated hemoglobin (HbA1c) levels are favored to monitor glycemic control.

High fasting glucose level in comparison to post practial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc. GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glycaemics & Insulin treatment, Renal Glycaemic & Insulin response & sensitivity etc.

treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc. Additional test HbA1c LIVER FUNCTION PROFILE, SERUM-

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. Elevated levels results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors &Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity.ALT test measures the amount of this enzyme in the blood.ALT is found mainly in the liver, but also in smaller amounts in the kidneys,heart,muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Pagets disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilsons disease. GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain

and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc.

Total Protein also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease.Lower-than-normal levels may be due to: Agammaglobulinemia,Bleeding (hemorrhage),Burns,Glomerulonephritis,Liver disease, Malabsorption,Malnutrition,Nephrotic syndrome, Protein-losing enteropathy etc.

Albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by:Liver disease like cirrhosis of the liver, nephrotic syndrome,protein-losing enteropathy,Burns,hemodilution,increased vascular permeability or decreased lymphatic clearance,malnutrition and wasting etc

BLODD UREA NITROGEN (BUN), SERUM-**Causes of Increased** levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism) **Causes of decreased** level include Liver disease, SIADH.

CREATININE, SERUM-**Higher than normal level may be due to:** • Blockage in the urinary tract, Kidney problems, such as kidney damage or failure, infection, or reduced blood flow, Loss of body fluid (dehydration), Muscle problems, such as breakdown of muscle fibers, Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia)

### Lower than normal level may be due to: Myasthenia Gravis, Muscuophy

URIC ACID, SERUM-Causes of Increased levels:-Dietary(High Protein Intake, Prolonged Fasting, Rapid weight loss), Gout, Lesch nyhan syndrome, Type 2 DM, Metabolic syndrome Causes of decreased levels-Low Zinc intake, OCP, Multiple Sclerosis

TOTAL PROTEIN, SERUM-is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin.

Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease. Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

## ALBUMIN, SERUM-

Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance,malnutrition and wasting etc.

S.S. Wadal

Dr. Sneha Wadalkar, M.D (Reg.no.MMC2012/06/1868) Junior Biochemist



Page 17 Of 24

View Report

/iew Details



**PERFORMED AT :** SRL Ltd PRIME SQUARE BUILDING, PLOT NO 1, GAIWADI INDUSTRIAL ESTATE, S.V. ROAD, GOREGAON (W) Mumbai, 400062 MAHARÁSHTRA, INDIA Tel : 9111591115, Fax CIN - U74899PB1995PLC045956





**PATIENT NAME: ANJANA KAURA REF. DOCTOR : SELF** ACCESSION NO : 0002WD011627 AGE/SEX :45 Years Female :07/04/2023 08:48:35 PATIENT ID : ANJAF0209772 DRAWN CLIENT PATIENT ID: RECEIVED :07/04/2023 08:50:01 ABHA NO REPORTED :10/04/2023 17:54:18 : **Test Report Status Final** Results **Biological Reference Interval** Units

ſ	CLINICAL PATH - URINALYSI	e	
MEDI WHEEL FULL BODY HEALTH CHECH			
PHYSICAL EXAMINATION, URINE			
COLOR	PALE YELLOW		
APPEARANCE	CLEAR		
CHEMICAL EXAMINATION, URINE			
РН	7.5	5.00 - 7.50	
SPECIFIC GRAVITY	1.005 Low	1.010 - 1.030	
PROTEIN	NOT DETECTED	NOT DETECTED	
GLUCOSE	NOT DETECTED	NOT DETECTED	
KETONES	NOT DETECTED	NOT DETECTED	
BLOOD	NOT DETECTED	NOT DETECTED	
BILIRUBIN	NOT DETECTED	NOT DETECTED	
UROBILINOGEN	NOT DETECTED		
NITRITE	NOT DETECTED	NOT DETECTED	
LEUKOCYTE ESTERASE	NOT DETECTED	NOT DETECTED	
MICROSCOPIC EXAMINATION, URINE			
RED BLOOD CELLS	NOT DETECTED	NOT DETECTED	/HPF
PUS CELL (WBC'S)	1-2	0-5	/HPF
EPITHELIAL CELLS	0-1	0-5	/HPF
CASTS	NOT DETECTED		
CRYSTALS	NOT DETECTED		
BACTERIA	NOT DETECTED	NOT DETECTED	
YEAST	NOT DETECTED	NOT DETECTED	
METHOD : URINE ROUTINE & MICROSCOPY EXAMINATION	N BY INTEGRATED AUTOMATED SYSTEM		

# Interpretation(s)

The following table describes the probable conditions, in which the analytes are present in urine

Presence of	Conditions
Proteins	Inflammation or immune illnesses
Pus (White Blood Cells)	Urinary tract infection, urinary tract or kidney stone, tumors or any kind of kidney impairment

S.S. Wadal

Dr. Sneha Wadalkar,M.D (Reg.no.MMC2012/06/1868) Junior Biochemist













 PATIENT NAME : ANJANA KAURA
 REF. DOCTOR : SELF

 ACCESSION NO : 0002WD011627
 AGE/SEX
 :45 Years
 Female

 PATIENT ID
 : ANJAF0209772
 DRAWN
 :07/04/2023
 08:48:35

 CLIENT PATIENT ID:
 REF. DOCTOR :
 RECEIVED
 :07/04/2023
 08:50:01

 ABHA NO
 :
 IONOV
 IONOV/2023
 17:54:18


Test Report Status <u>Final</u> Results

Biological Reference Interval Units

Glucose	Diabetes or kidney disease
Ketones	Diabetic ketoacidosis (DKA), starvation or thirst
Urobilinogen	Liver disease such as hepatitis or cirrhosis
Blood	Renal or genital disorders/trauma
Bilirubin	Liver disease
Erythrocytes	Urological diseases (e.g. kidney and bladder cancer, urolithiasis), urinary tract infection and glomerular diseases
Leukocytes	Urinary tract infection, glomerulonephritis, interstitial nephritis either acute or chronic, polycystic kidney disease, urolithiasis, contamination by genital secretions
Epithelial cells	Urolithiasis, bladder carcinoma or hydronephrosis, ureteric stents or bladder catheters for prolonged periods of time
Granular Casts	Low intratubular pH, high urine osmolality and sodium concentration, interaction with Bence-Jones protein
Hyaline casts	Physical stress, fever, dehydration, acute congestive heart failure, renal diseases
Calcium oxalate	Metabolic stone disease, primary or secondary hyperoxaluria, intravenous infusion of large doses of vitamin C, the use of vasodilator naftidrofuryl oxalate or the gastrointestinal lipase inhibitor orlistat, ingestion of ethylene glycol or of star fruit (Averrhoa carambola) or its juice
Uric acid	arthritis
Bacteria	Urinary infectionwhen present in significant numbers & with pus cells.
Trichomonas vaginalis	Vaginitis, cervicitis or salpingitis

g.g.wadal

Dr. Sneha Wadalkar,M.D (Reg.no.MMC2012/06/1868) Junior Biochemist



Page 19 Of 24











 PATIENT NAME : ANJANA KAURA
 REF. DOCTOR : SELF

 ACCESSION NO : 0002WD011627
 AGE/SEX : 45 Years
 Female

 PATIENT ID : ANJAF0209772
 DRAWN :07/04/2023 08:48:35
 CLIENT PATIENT ID:

 ABHA NO :
 ABHA NO :
 REPORTED :10/04/2023 17:54:18

Test Report Status	<u>Final</u>	Results	<b>Biological Reference Interval</b>	Units

c	LINICAL PATH - STOOL ANALY	/SIS		
MEDI WHEEL FULL BODY HEALTH CHEC	KUP ABOVE 40FEMALE			
PHYSICAL EXAMINATION, STOOL				
COLOUR	DARK BROWN			
CONSISTENCY	WELL FORMED			
MUCUS	NOT DETECTED	NOT DETECTED		
VISIBLE BLOOD	ABSENT	ABSENT		
ADULT PARASITE	NOT DETECTED			
METHOD : MICROSCOPIC EXAMINATION				
CHEMICAL EXAMINATION, STOOL				
STOOL PH	6.0			
OCCULT BLOOD	NOT DETECTED	NOT DETECTED		
METHOD : MODIFIED GUAIAC METHOD				
MICROSCOPIC EXAMINATION, STOOL				
PUS CELLS	0-1		/hpf	
RED BLOOD CELLS	NOT DETECTED	NOT DETECTED	/HPF	
METHOD : MICROSCOPIC EXAMINATION				
CYSTS	NOT DETECTED	NOT DETECTED		
METHOD : MICROSCOPIC EXAMINATION				
OVA METHOD : MICROSCOPIC EXAMINATION	NOT DETECTED			
LARVAE	NOT DETECTED	NOT DETECTED		
	NOT DETECTED			
TROPHOZOITES	NOT DETECTED	NOT DETECTED		
METHOD : MICROSCOPIC EXAMINATION				
FAT	ABSENT			
CHARCOT LEYDEN CRYSTALS	ABSENT			
Interpretation(s)				

# Interpretation(s)

Stool routine analysis is only a screening test for disorders of gastrointentestinal tract like infection, malabsorption, etc. The following table describes the probable conditions, in which the analytes are present in stool.

PRESENCE OF	CONDITION
Pus cells	Pus in the stool is an indication of infection

Dr. Sukanya Verma (Reg.No.MMC2012/03/0443) Consultant Microbiologist





Page 20 Of 24



PERFORMED AT : SRL Ltd PRIME SQUARE BUILDING,PLOT NO 1,GAIWADI INDUSTRIAL ESTATE,S.V. ROAD,GOREGAON (W) Mumbai, 400062 MAHARASHTRA, INDIA Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956 **Test Report Status** 

<u>Final</u>





Units

PATIENT NAME: ANJANA KAURA **REF. DOCTOR : SELF** ACCESSION NO : 0002WD011627 AGE/SEX :45 Years Female PATIENT ID DRAWN :07/04/2023 08:48:35 : ANJAF0209772 CLIENT PATIENT ID: RECEIVED :07/04/2023 08:50:01 ABHA NO REPORTED :10/04/2023 17:54:18 : Results Biological Reference Interval

Red Blood cells	Parasitic or bacterial infection or an inflammatory bowel condition such as ulcerative colitis	
Parasites	Infection of the digestive system. Stool examination for ova and parasite detects presence of parasitic infestation of gastrointestinal tract. Various forms of parasite that can be detected include cyst, trophozoite and larvae. One negative result does not rule out the possibility of parasitic infestation. Intermittent shedding of parasites warrants examinations of multiple specimens tested on consecutive days. Stool specimens for parasitic examination should be collected before initiation of antidiarrheal therapy or antiparasitic therapy. This test does not detect presence of opportunistic parasites like Cyclospora, Cryptosporidia and Isospora species. Examination of Ova and Parasite has been carried out by direct and concentration techniques.	
Mucus	Mucus is a protective layer that lubricates, protects& reduces damage due to bacteria or viruses.	
Charcot-Leyden crystal	Parasitic diseases.	
Ova & cyst	Ova & cyst indicate parasitic infestation of intestine.	
Frank blood	Bleeding in the rectum or colon.	
Occult blood	Occult blood indicates upper GI bleeding.	
Macrophages	Macrophages in stool are an indication of infection as they are protective cells.	
Epithelial cells	Epithelial cells that normally line the body surface and internal organs show up in stool when there is inflammation or infection.	
Fat	Increased fat in stool maybe seen in conditions like diarrhoea or malabsorption.	
pH	Normal stool pH is slightly acidic to neutral. Breast-fed babies generally have an acidic stool.	

# **ADDITIONAL STOOL TESTS :**

- 1. Stool Culture:- This test is done to find cause of GI infection, make decision about best treatment for GI infection & to find out if treatment for GI infection worked.
- Fecal Calprotectin: It is a marker of intestinal inflammation. This test is done to differentiate Inflammatory Bowel Disease (IBD) 2. from Irritable Bowel Syndrome (IBS).
- Fecal Occult Blood Test(FOBT): This test is done to screen for colon cancer & to evaluate possible cause of unexplained anaemia. 3.
- Clostridium Difficile Toxin Assay: This test is strongly recommended in healthcare associated bloody or waterydiarrhoea, due to 4. overuse of broad spectrum antibiotics which alter the normal GI flora.
- 5. Biofire (Film Array) GI PANEL: In patients of Diarrhoea, Dysentry, Rice watery Stool, FDA approved, Biofire Film Array Test, (Real Time Multiplex PCR) is strongly recommended as it identifies organisms, bacteria, fungi, virus, parasite and other opportunistic pathogens, Vibrio cholera infections only in 3 hours. Sensitivity 96% & Specificity 99%.
- Rota Virus Immunoassay: This test is recommended in severe gastroenteritis in infants & children associated with watery 6. diarrhoea, vomitting& abdominal cramps. Adults are also affected. It is highly contagious in nature.

Dr. Sukanya Verma (Reg.No.MMC2012/03/0443) **Consultant Microbiologist** 



View Repor

Page 21 Of 24







**REF. DOCTOR : SELF PATIENT NAME: ANJANA KAURA** ACCESSION NO : 0002WD011627 AGE/SEX :45 Years Female PATIENT ID DRAWN :07/04/2023 08:48:35 : ANJAF0209772 CLIENT PATIENT ID: RECEIVED :07/04/2023 08:50:01 ABHA NO REPORTED :10/04/2023 17:54:18 : **Test Report Status** Results **Biological Reference Interval** Units <u>Final</u>

SPECIALISED CHEMISTRY - HORMONE						
MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE						
97.7	2nd Trimester:129.0 - 262.	.0				
ENCE IMMUNOASSAY						
7.52	2nd Trimester: 7.93 - 16.10	0				
ENCE IMMUNOASSAY						
3.620	Non Pregnant Women 0.27 - 4.20 Pregnant Women 1st Trimester: 0.33 - 4.59 2nd Trimester: 0.35 - 4.10 3rd Trimester: 0.21 - 3.15	µIU/mL				
E	97.7 ENCE IMMUNOASSAY 7.52	97.7       Non-Pregnant Women         80.0 - 200.0       Pregnant Women         1st Trimester:105.0 - 230.0       2nd Trimester:129.0 - 262.0         2nd Trimester:129.0 - 262.0       3rd Trimester:135.0 - 262.0         ENCE IMMUNOASSAY       7.52         7.52       Non-Pregnant Women         5.10 - 14.10       Pregnant Women         1st Trimester: 7.33 - 14.80       2nd Trimester: 7.93 - 16.10         2nd Trimester: 6.95 - 15.70       3.620         Non Pregnant Women       0.27 - 4.20         Pregnant Women       1st Trimester: 0.33 - 4.59         2nd Trimester: 0.35 - 4.10				

# Interpretation(s)

**Triiodothyronine T3**, **Thyroxine T4**, and **Thyroid Stimulating Hormone TSH** are thyroid hormones which affect almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate.

Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH.

Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hyperthyroidism, TSH levels are low. Below mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3.Measurement of the serum TT3 level is a more sensitive test for the diagnosis of hyperthyroidism, and measurement of TT4 is more useful in the diagnosis of hypothyroidism.Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically active. It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.

	Sr. No.	TSH	Total T4	FT4	Total T3	Possible Conditions
--	---------	-----	----------	-----	----------	---------------------

.S.wadal

Dr. Sneha Wadalkar,M.D (Reg.no.MMC2012/06/1868) Junior Biochemist



Page 22 Of 24

Vie<u>w Report</u>





PERFORMED AT : SRL Ltd PRIME SQUARE BUILDING,PLOT NO 1,GAIWADI INDUSTRIAL ESTATE,S.V. ROAD,GOREGAON (W) Mumbai, 400062 MAHARASHTRA, INDIA Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956





MC-2010

PATIENT NAME : ANJANA KAURA	REF. DOCTOR : SELF		
	ACCESSION NO : 0002WD011627	AGE/SEX : 45 Years Female	
	PATIENT ID : ANJAF0209772	DRAWN :07/04/2023 08:48:35	
	CLIENT PATIENT ID:	RECEIVED : 07/04/2023 08:50:01	
	ABHA NO :	REPORTED :10/04/2023 17:54:18	
Test Report Status <u>Final</u>	Results Biological	Reference Interval Units	


1	High	Low	Low	Low	(1) Primary Hypothyroidism (2) Chronic autoimmune Thyroiditis (3)	
		0- 01			Post Thyroidectomy (4) Post Radio-Iodine treatment	
2	High	Normal	Normal	Normal	(1)Subclinical Hypothyroidism (2) Patient with insufficient thyroid hormone replacement therapy (3) In cases of Autoimmune/Hashimoto thyroiditis (4). Isolated increase in TSH levels can be due to Subclinical inflammation, drugs like amphetamines, Iodine containing drug and dopamine antagonist e.g. domperidone and other physiological reasons.	
3	Normal/Low	Low	Low	Low	(1) Secondary and Tertiary Hypothyroidism	
4	Low	High	High	High	<ul> <li>(1) Primary Hyperthyroidism (Graves Disease) (2) Multinodular Goitre</li> <li>(3) Toxic Nodular Goitre (4) Thyroiditis (5) Over treatment of thyroid hormone (6) Drug effect e.g. Glucocorticoids, dopamine, T4 replacement therapy (7) First trimester of Pregnancy</li> </ul>	
5	Low	Normal	Normal	Normal	(1) Subclinical Hyperthyroidism	
6	High	High	High	High	(1) TSH secreting pituitary adenoma (2) TRH secreting tumor	
7	Low	Low	Low	Low	(1) Central Hypothyroidism (2) Euthyroid sick syndrome (3) Recent treatment for Hyperthyroidism	
8	Normal/Low	Normal	Normal	High	(1) T3 thyrotoxicosis (2) Non-Thyroidal illness	
9	Low	High	High	Normal	(1) T4 Ingestion (2) Thyroiditis (3) Interfering Anti TPO antibodies	

REF: 1. TIETZ Fundamentals of Clinical chemistry 2. Guidlines of the American Thyroid association during pregnancy and Postpartum, 2011. NOTE: It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.TSH is not affected by variation in thyroid - binding protein. TSH has a diurnal rhythm, with peaks at 2:00 - 4:00 a.m. And troughs at 5:00 - 6:00 p.m. With ultradian variations.

> \*\*End Of Report\*\* Please visit www.srlworld.com for related Test Information for this accession

S.S. Wadal

Dr. Sneha Wadalkar, M.D (Reg.no.MMC2012/06/1868) Junior Biochemist







View Report

Page 23 Of 24







**REF. DOCTOR : SELF PATIENT NAME: ANJANA KAURA** ACCESSION NO : 0002WD011627 AGE/SEX :45 Years Female :07/04/2023 08:48:35 PATIENT ID : ANJAF0209772 DRAWN CLIENT PATIENT ID: RECEIVED :07/04/2023 08:50:01 ABHA NO REPORTED :10/04/2023 17:54:18 : **Test Report Status** Results Biological Reference Interval Units **Final** 

# **CONDITIONS OF LABORATORY TESTING & REPORTING**

 It is presumed that the test sample belongs to the patient named or identified in the test requisition form.
 All tests are performed and reported as per the turnaround time stated in the SRL Directory of Services.
 Result delays could occur due to unforeseen circumstances such as non-availability of kits / equipment breakdown / natural calamities / technical downtime or any other unforeseen event.

## 4. A requested test might not be performed if:

- i. Specimen received is insufficient or inappropriate
- ii. Specimen quality is unsatisfactory
- iii. Incorrect specimen type

iv. Discrepancy between identification on specimen container label and test requisition form

5. SRL confirms that all tests have been performed or assayed with highest quality standards, clinical safety & technical integrity.

6. Laboratory results should not be interpreted in isolation; it must be correlated with clinical information and be interpreted by registered medical practitioners only to determine final diagnosis.

7. Test results may vary based on time of collection, physiological condition of the patient, current medication or nutritional and dietary changes. Please consult your doctor or call us for any clarification.

Test results cannot be used for Medico legal purposes.
 In case of queries please call customer care


(91115 91115) within 48 hours of the report.

## SRL Limited

Fortis Hospital, Sector 62, Phase VIII, Mohali 160062

.S. Wadal

Dr. Sneha Wadalkar,M.D (Reg.no.MMC2012/06/1868) Junior Biochemist



Page 24 Of 24





View Repor

